Success Story Podcast Announces New Episode Featuring Billionaire Grant Cardone on Wealth and Leadership
Billionaire Real Estate Mogul Grant Cardone Reveals Why He "Should Be Worth $20 Billion Today" and Shares Unconventional Success Blueprint
$4 Billion Empire Builder Discusses Breaking Comfort Zone Addiction, Choosing the Right "Vehicle" for Wealth, and Why Most People Have "Quit on Money"
Cardone also hints at major announcement coming "within the week" and reconsiders California political ambitions
Miami, Florida , June 10, 2025 (GLOBE NEWSWIRE) -- Success Story Podcast, hosted by Scott Clary, has announced a new episode featuring billionaire entrepreneur and Cardone Ventures CEO Grant Cardone. In this exclusive conversation, Cardone shares unfiltered insights on building generational wealth, the hidden challenges of leadership, and the mindset shifts that separate top performers from the rest. The episode offers listeners a candid look at Cardone's personal journey and practical strategies for achieving extraordinary success.
Grant Cardone, the outspoken billionaire behind a $4 billion real estate empire and bestselling author of "The 10X Rule," delivered hard-hitting insights about wealth creation, leadership isolation, and the critical decisions that separate the ultra-successful from everyone else in a revealing interview on Scott Clary's Success Story podcast.
The $20 Billion Revelation
In a candid moment, Cardone stated he "should be worth $20 billion today," attributing the gap to strategic vehicle choices rather than effort or mindset. "The difference between me and my friend who gained $9 billion in two weeks isn't the mindset – we both want abundance and to help millions of people. The difference is the vehicle," Cardone explained, referencing a friend who recently experienced massive volatility, gaining $5 billion in one day before losing $6 billion the following Friday.
The Comfort Zone Trap
Cardone identified "comfort" as a dangerous addiction that prevents breakthrough success. "Comfortable is a serious addiction that allows you to socially drift through life. You're on a drug of 'I don't want to take risk, I don't want to feel stressed, I just want enough,'" he warned. He revealed that even after making his first million dollars, he fell into this trap: "I went into conservation mode, not hunger mode. What I should have done is 10X that million."
Why Most People Have "Quit on Money"
Addressing widespread financial struggles, particularly citing Toronto's housing crisis where million-dollar condos are unattainable for $70K earners, Cardone argued that most people have psychologically given up on wealth creation. "I think most people have quit on the money game. They're like, 'I'm not going to have it. The game's rigged. I just need to be happy,'" he observed.
His solution is radical target-setting: "Your target should be monster. Make a 100X exit. Then find out whether the business you're in right now can actually get you to that target."
The Leadership Loneliness Factor
Cardone opened up about the isolation that comes with high-level decision-making, comparing his experience to Donald Trump's situation. "Do you know how lonely Donald Trump must be? There is no way that guy's doing what he's doing on a daily basis that he gets support from everybody around him," he reflected. "If you're in a leadership position, you're going to be in a situation one day where you got to go take a hill and you're going to look up – you're by yourself."
Controversial Education and Parenting Philosophy
The billionaire continued his criticism of traditional education paths, stating most people "should not go to college" and calling the current system "insanity." For parenting, he advocates extreme engagement: "You cannot turn them over to YouTube and Facebook. Those are not nannies. Get your kids off TV, get your kids off YouTube, get your kids active."
Cardone homeschools his children year-round and requires them to work under contract since age six, resulting in his 15-year-old daughter graduating high school at 15.
Political Ambitions in Question
In a rare moment of uncertainty, Cardone revealed he's "second-guessing the whole California thing," referring to his consideration of entering California politics to "flip it red." Despite believing he "could win it," he's questioning whether to pursue the opportunity given other priorities.
The Ultimate Success Formula
When asked for the single most important lesson he'd pass to his children, Cardone delivered his core philosophy: "You will never get anything great without leaving something good."
About Success Story Podcast
The Success Story podcast, hosted by Scott Clary, features in-depth conversations with the world's most successful entrepreneurs, investors, and business leaders. Known for extracting actionable insights and candid revelations, the show has become a premier destination for ambitious professionals seeking real-world business wisdom.
Watch the full interview: https://youtu.be/yN8lVm9mivo?si=h4JaexJoTkwAlcJQ
About Grant Cardone
Grant Cardone is a New York Times bestselling author, sales expert, real estate investor, and entrepreneur who has built a $4 billion real estate portfolio. He is the founder and CEO of Cardone Capital and Cardone Ventures, and the author of several business books including "The 10X Rule." Known for his no-nonsense approach to business and wealth building, Cardone has trained Fortune 500 companies and speaks to hundreds of thousands annually about sales, business, and success strategies.
About Success Story Podcast The Success Story Podcast is hosted by entrepreneur, business executive, author, educator and speaker Scott D. Clary. On Success Story, he conducts candid conversations with some of the most prolific business and thought leaders in the world. The podcast ranks as a Top 10 business podcast and Top 3 Education/Self Development podcast, with over 50 million downloads. It is part of the HubSpot Podcast Network and Cheddar. Clary's weekly business newsletter reaches over 321,000 subscribers, sharing valuable insights from his experiences throughout his career.
Press inquiries
Success Story Podcast https://successstorypodcast.com Scott D. Clary scott@scottdclary.com
A video accompanying this announcement is available at https://youtube.com/embed/yN8lVm9mivo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token
By GlobeNewswire Published on June 15, 2025, 13:20 IST SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) — Vaultro Finance has just announced a landmark achievement in its public sale of the native utility token VLT. The $VLT presale Round has now achieved a 50% sale milestone, marking a pivotal moment in the project's journey and sending a clear signal that investor demand is surging. Achieving half of the targeted hardcap in rapid fashion underscores the market's enthusiasm for Vaultro's revolutionary approach to decentralized index fund investing on the XRP Ledger. Purchase $VLT Token on Presale Round This breakthrough comes amid a broader upswing for XRP itself. The token continues to trade above $2.10, supported by growing institutional inflows and the expanding suite of XRP based exchange traded products worldwide. Regulatory headwinds have given way to clarity, and major markets are embracing XRP infrastructure. In this revitalized environment, Vaultro Finance stands out by delivering real world utility in the form of a fully on chain index fund protocol. The $VLT Token Presale milestone of 50% claimed demonstrates that investors are seeking projects which combine familiar financial logic with the transparency and efficiency of blockchain. At the heart of the Vaultro ecosystem is the VLT token , VLT holders unlock rights that extend far beyond simple token ownership. They gain the ability to create their own custom index funds, selecting themes such as artificial intelligence tokens, stablecoins for stability, decentralized finance protocols capturing the next wave of innovation, and high potential XRPL assets. VLT token holders also participate directly in governance, voting on platform upgrades, new fund listings, and strategic decisions that shape the protocol's future. Participate in $VLT Presale at Discount Rate Participation in the presale remains open but is advancing toward its halfway point. Prospective contributors must hold an XRP native wallet and set up a trustline for the VLT token by following the step by step guideline, A minimum contribution of 200 XRP ensures broad accessibility. The official presale portal at is available now for anyone ready to join. Do not miss your chance to be part of the next wave of decentralized finance on the XRP Ledger. Secure your VLT tokens today and help define the future of on chain index fund management. For more details on Vaultro Finance and the $VLT presale visit; Website Join $VLT Presale X fka Twitter Telegram Community Whitepaper Blog Channel Contact:Lee Wang [email protected] Disclaimer: This is a paid post and is provided by Vaultro Finance. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
4 hours ago
- Business Upturn
Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap
By GlobeNewswire Published on June 15, 2025, 15:45 IST TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) — Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch now just weeks away. With over $4.5 million already raised and more than 11,500 participants onboard, momentum is surging. Final Opportunity Before Public Launch The presale is currently in Phase 7's last day , with BTC-S tokens priced at $7. The next presale phase will raise the price to $8, with a launch price set at $20. This structured pricing reflects strong demand and limited availability, given the project's fixed supply of 21 million tokens—identical in scarcity to the original Bitcoin. With fewer than eight weeks remaining before public launch, this is the last opportunity for early supporters to participate before BTC-S becomes tradable on major platforms. A Scarcity-Driven Token Built for Scalability Bitcoin Solaris takes the best parts of Bitcoin, the 21 million supply cap, and upgrades everything else. While Bitcoin transactions take about 10 minutes to finalize, Bitcoin Solaris pushes blocks every 15 seconds and confirms them in under 2 seconds. This performance comes from a hybrid structure that combines a Proof-of-Work Base Layer with a high-throughput Delegated Proof-of-Stake Solaris Layer. This dual-consensus model: Supports 10,000+ TPS Slashes energy usage by over 99.95% compared to Bitcoin Enables lightning-fast smart contract execution Rotates validators based on weighted contribution and uptime It's the kind of blockchain performance that fits perfectly in a bull market narrative—fast, efficient, and decentralized. A Smarter, Faster, Fairer Bitcoin Is Here—Step Into BTC-S Tokenomics That Ignite Long-Term Demand Beyond the tech, Bitcoin Solaris backs its vision with powerful tokenomics. The hard cap of 21 million BTC-S tokens mirrors Bitcoin's scarcity, but the utility goes far beyond holding. Here's how the tokenomics create upward pressure: Tokens are required for staking, validating, and interacting with the ecosystem Time-weighted validator rewards encourage long-term holding No inflationary print cycles—only mined or earned tokens The low total supply paired with strong use cases builds consistent demand BTC-S isn't just another asset to flip, it's a network to participate in. Referral-Driven Growth Fueling Viral Expansion Bitcoin Solaris's Double Rewards Referral Program is a major catalyst behind its exponential community growth. Here's how it works: Anyone who refers new investors earns 5% of their purchases in BTC-S tokens New users who join via a referral also get 5% bonus tokens All rewards are credited automatically via the user dashboard on This viral mechanic has powered over 11,500 users to join the presale in just weeks, turning BTC-S into one of the fastest-growing ecosystems of this cycle. The community is now spreading across Telegram and X , further accelerating its altcoin season momentum. Presale Is Almost Over: The Window Is Closing A detailed video review by 2Bit Crypto breaks down exactly why BTC-S is gaining this much traction—including its audit-approved smart contracts and high-performance infrastructure. The Engine of Wealth in Altcoin Season What sets Bitcoin Solaris apart in this altcoin season isn't just hype—it's architecture. By allowing anyone to participate in mining from a laptop , browser, or upcoming mobile platform, it reduces barriers for earning crypto at scale. Its validator reward structure balances decentralization and speed. Blocks are mined via Proof-of-Work, then delegated for verification in a DPoS layer with built-in slashing and validator rotation. This ensures fair payouts, lower risks, and a healthy ecosystem long-term. Add in audits from Cyberscope and Freshcoins , and you've got one of the most technically complete altcoins on the rise. Conclusion Altcoin season is known for turning obscure projects into household names. With Bitcoin Solaris, we're watching that transformation in real time. It blends Bitcoin's scarcity with elite performance, DeFi-ready tokenomics, and viral growth mechanics. As the presale comes to a close, BTC-S is looking more and more like the best coin of this cycle. For more information on Bitcoin Solaris: Website: Telegram: X: Media Contact:Xander Levine [email protected] Press Kit: Available upon request Disclaimer: This is a paid post and is provided by Bitcoin Solaris . The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
4 hours ago
- Business Upturn
Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs1 Advertisement BEERSE, BELGIUM, June 15, 2025 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson company, announced today new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY®▼(talquetamab), the first European Commission (EC) approved GPRC5D-directed bispecific antibody, and TECVAYLI®▼(teclistamab), the first EC approved BCMA-directed bispecific antibody. The results show a high overall response rate (ORR) with durability in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who have true extramedullary disease (EMD).1 EMD is defined as soft tissue/organ-associated plasmacytomas with no contact to bony structures as per International Myeloma Working Group (IMWG) criteria.2 RedirecTT-1 is the largest study dedicated to patients with EMD to date.1 These data were featured in a late-breaking oral presentation (Abstract #LB4001) at the 2025 European Hematology Association (EHA) Congress.1 EMD represents an aggressive form of multiple myeloma and occurs when myeloma cells spread and form tumours (plasmacytomas) elsewhere in the body, such as in soft tissues and organs.3 These patients often face limited treatment options and worse outcomes due to the complexity of the disease, including tumour heterogeneity, resulting in low ORRs and rapid relapses with current standard therapies.2,3 On average, TCE RRMM patients with EMD have an ORR of less than 40 percent and a median progression-free survival (PFS) of less than six months.4 'The investigational combination of talquetamab and teclistamab has demonstrated deep, durable responses in patients with relapsed or refractory multiple myeloma, and now shows great promise in those with extramedullary myeloma, where standard therapies often fall short,' said Yael Cohen, M.D., Head of Myeloma Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.* 'Dual targeting of GPRC5D and BCMA may lead to a higher ORR and greater depth of response by mitigating target antigen-related escape. The RedirecTT-1 trial shows the power of this novel dual-targeting combination approach as a potential treatment option for patients with this disease.' The Phase 2 RedirecTT-1 study enrolled 90 patients with TCE RRMM with true EMD.1 Of these patients, 84.4 percent were triple-class refractory, 35.6 percent were penta-drug refractory, 20.0 percent had previously received BCMA CAR-T therapy, and 8.9 percent had previously received a bispecific antibody.1 The investigational combination of talquetamab and teclistamab led to a high ORR of 78.9 percent (95 percent confidence interval [CI]; 69.0–86.8), with more than half of patients (54.4 percent) achieving complete response or better.1 High responses were observed even in patients exposed to prior BCMA CAR-T or anti-FcRH5 bispecific antibodies (83.3 percent ORR; 58.6-96.4 and 75.0 percent ORR; 34.9-96.8, respectively).1 Among responders, 66.2 percent remained in response at the data cutoff, with a median follow-up of 13.4 months, signalling deep and durable responses.1 Treatment with the combination resulted in 61.0 percent of patients progression-free and alive at one year.1 Additionally, the combination led to durable responses, with 64.1 percent of patients maintaining response (median duration of response: 13.8 months) and 74.5 percent of patients alive at one year, while median overall survival was not yet reached.1 'Multiple myeloma remains a complex and heterogeneous disease, with extramedullary disease presenting a particularly aggressive and challenging to treat form,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology at Johnson & Johnson Innovative Medicine. 'The RedirecTT-1 study reflects our strategy to harness novel mechanisms of action, such as the combination of these dual bispecific antibodies, to help redefine potential outcomes for subsets of patients who are currently faced with a poor prognosis and limited options.' The safety profile of the combination was consistent with previous reports of talquetamab and teclistamab as monotherapies, with no new safety signals identified.1 Patients were given the option to switch to once a month dosing potentially contributing to improved tolerability.1 Rates of discontinuation were low with the treatment combination of talquetamab and teclistamab due to adverse events (AEs).1 Four participants discontinued talquetamab only.1 Reports of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade.1 Of the ten patients who had Grade 5 AEs (11.1 percent), five were due to infections.1 There were five patient deaths due to infection and the rates of severe infection were similar to those observed with some BCMA bispecific antibody monotherapies.1 'Patients with extramedullary myeloma, especially those who have exhausted prior therapies, need more effective treatment options,' said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine. 'Our first-in-class bispecific antibodies talquetamab and teclistamab have transformed treatment for relapsed or refractory multiple myeloma. The RedirecTT-1 study underscores our commitment to advancing innovative therapies that attack the disease in different ways by building combinable and complementary regimens.' About Talquetamab Talquetamab received conditional marketing authorisation (CMA) from the European Commission (EC) in August 2023, as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.5 The U.S. Food and Drug Administration (FDA) also granted talquetamab approval in August 2023, for the treatment of adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.6 Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 on the surface of T-cells, and GPRC5D, a novel target which is highly expressed on the surface of multiple myeloma cells, with minimal to no expression detected on B-cells or B-cell precursors.5 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using talquetamab, please refer to the Summary of Product Characteristics. In line with European Medicine Agency (EMA) regulations for new medicines and those given conditional approval, talquetamab is subject to additional monitoring. About Teclistamab Teclistamab received EC approval in August 2022 for the treatment of patients with RRMM who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.7 In August 2023, the EC approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months.8 Teclistamab received approval from the U.S. FDA in October 2022 for the treatment of adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.9 Teclistamab is an off-the-shelf (or ready-to-use) bispecific antibody.9,10 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's immune system to fight the cancer. Teclistamab is currently being evaluated in several combination studies.10,11,12,13,14 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using teclistamab, please refer to the Summary of Product Characteristics. In line with European Medicine Agency (EMA) regulations for new medicines and those given conditional approval, teclistamab is subject to additional monitoring. About Multiple Myeloma Multiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.15,16 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications.15,16 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died.17 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy18,19 while remissions become progressively shorter.18,19,20 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage.21 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at Follow us at Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of teclistamab and talquetamab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. * Yael Cohen, M.D., Head of Myeloma Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel., has provided consulting, advisory and speaking services to Janssen-Cilag International NV; she has not been paid for any media work. ### 1 Kumar S, et al. Phase 2 study of Talquetamab + Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma with Extramedullary Disease: presentation at 2025 European Hematology Association (EHA) Congress; June 12-15, 2025. 2 Ho M, et Multiple Myeloma: Challenges and Opportunities. Curr. Oncol, 2025; 32: 182. 3 Blade J, et al. Extramedullary Disease in Multiple Myeloma: a Systematic Literature Review. Blood Cancer J, 2022; 12(3):45. 4 Moreau P, et al. Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies. Clinical Lymphoma, Myeloma and Leukemia, 2025; 25: S2152-2650. 5 European Medicines Agency. TALVEY Summary of Product Characteristics. Available at: Last accessed: June 2025. 6 FDA. FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma. Available at: Last accessed: June 2025. 7 Janssen Marks First Approval Worldwide. Available at: Last accessed: June 2025. 8 European Commission Approves Reduced Dosing Frequency for Janssen's Bispecific Antibody TECVAYLI®▼ (teclistamab). Available at: Last accessed: June 2025. 9 U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Available at: Last accessed: June 2025. 10 European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: Last accessed: June 2025. 11 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: Last accessed: June 2025. 12 A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: Last accessed: June 2025. 13 A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: Last accessed: June 2025. 14 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (TecDara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: Last accessed: June 2025. 15 Abdi J, et al. Drug Resistance in Multiple Myeloma: Latest Findings on Molecular Mechanisms. Oncotarget 2013;4(12):2186-2207. 16 American Society of Clinical Oncology. Multiple Myeloma: Introduction. Available at: Last accessed: June 2025. 17 ECIS – European Cancer Information System. Estimates of Cancer Incidence and Mortality in 2022, by Country. Multiple Myeloma. Available at: Last accessed: June 2025. 18 Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347. 19 Hernández-Rivas JÁ, et al. The Changing Landscape of Relapsed and/or Refractory Multiple Myeloma (MM): Fundamentals and Controversies. Biomark Res. 2022;10(1):1-23. 20 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430. 21 American Cancer Society. Multiple Myeloma: Early Detection, Diagnosis and Staging. Available at: Last accessed: June 2025. CP-526056 June 2025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
